Levosulpiride vs Itopride Side Effects
Levosulpiride carries a significantly higher risk of serious neurological adverse effects, particularly extrapyramidal symptoms (tremor, stiffness, dystonia) and hyperprolactinemia, compared to itopride which demonstrates a superior safety profile with minimal adverse events.
Key Safety Differences
Levosulpiride Side Effects
Neurological complications are the primary concern:
- Extrapyramidal symptoms occur frequently, including tremor, stiffness, acute dystonia, dysarthria, and parkinsonism 1
- A prospective study found these movement disorders correlate significantly with treatment duration (r = 0.8295, P = 0.0154), meaning longer use substantially increases risk 1
- Hyperprolactinemia is the major drawback, occurring in approximately 26.7% of patients, leading to galactorrhea 2, 3
- Other common effects include somnolence (17.8%), fatigue (11.1%), and headache (11.5%) 2
Critical clinical caveat: The British Society of Gastroenterology guidelines specifically note that levosulpiride requires "careful explanation as to the rationale for their use and patients should be counselled about their side effect profile" 4. This warning reflects the seriousness of potential adverse events.
Itopride Side Effects
Itopride demonstrates markedly better tolerability:
- Predominantly gastrointestinal side effects (the majority of adverse events) 5
- Prolactin elevations occur in only 3% of cases and are not clinically significant 5
- No ECG changes identified in long-term studies 5
- No serious adverse effects reported in multiple trials 6, 7, 8
- Compliance rates exceed 95% in long-term studies, indicating excellent tolerability 5
Evidence Quality and Clinical Implications
The British Society of Gastroenterology guidelines rate itopride with low quality evidence but acknowledge it is "well tolerated" 4. In contrast, levosulpiride is positioned as a second-line treatment specifically because of its side effect profile 4.
Direct comparative evidence from a 2022 network meta-analysis showed both drugs are effective for functional dyspepsia, but the safety profiles differ substantially 9. While levosulpiride ranked highest for efficacy, this must be balanced against its neurological risks.
Practical Clinical Algorithm
For initial prokinetic therapy:
- Start with itopride (100 mg three times daily) given superior safety profile
- Reserve levosulpiride (25 mg three times daily) for refractory cases only
- If levosulpiride is necessary, counsel patients explicitly about movement disorder risks
- Monitor closely for tremor, stiffness, or galactorrhea
- Consider drug holidays (1-4 weeks every 8-12 weeks) if using levosulpiride long-term
Red flags requiring immediate levosulpiride discontinuation:
- Any new-onset tremor or stiffness
- Dystonic reactions
- Galactorrhea or menstrual irregularities
- Parkinsonian symptoms
The evidence consistently demonstrates that itopride's dual mechanism (D2 antagonism plus acetylcholinesterase inhibition) provides prokinetic benefits without the severe dopaminergic blockade that causes levosulpiride's neurological complications 6, 7, 5.